Kite Pharma, Inc. (NASDAQ:KITE) EVP Helen Susan Kim sold 79,949 shares of the company’s stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $119.56, for a total transaction of $9,558,702.44. Following the transaction, the executive vice president now owns 98,613 shares in the company, valued at approximately $11,790,170.28. The sale was disclosed in a filing with the SEC, which is available at this link.
Helen Susan Kim also recently made the following trade(s):
- On Monday, July 31st, Helen Susan Kim sold 26,649 shares of Kite Pharma stock. The shares were sold at an average price of $109.28, for a total transaction of $2,912,202.72.
Shares of Kite Pharma, Inc. (NASDAQ:KITE) opened at 120.04 on Friday. Kite Pharma, Inc. has a one year low of $39.82 and a one year high of $122.19. The stock’s market capitalization is $6.86 billion. The company’s 50-day moving average is $107.82 and its 200-day moving average is $81.83.
Kite Pharma (NASDAQ:KITE) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, beating analysts’ consensus estimates of ($1.97) by $0.03. The business had revenue of $10.10 million for the quarter, compared to analysts’ expectations of $9.59 million. Kite Pharma had a negative net margin of 1,117.44% and a negative return on equity of 59.56%. The company’s quarterly revenue was up 110.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.91) EPS. On average, equities research analysts anticipate that Kite Pharma, Inc. will post ($8.35) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This story was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://transcriptdaily.com/2017/08/13/kite-pharma-inc-kite-evp-sells-9558702-44-in-stock.html.
A number of research analysts have issued reports on the stock. Jefferies Group LLC restated a “buy” rating and set a $135.00 price target (up previously from $121.00) on shares of Kite Pharma in a research note on Wednesday. Stifel Nicolaus restated a “hold” rating and set a $74.00 price target on shares of Kite Pharma in a research note on Thursday. Canaccord Genuity set a $120.00 price target on shares of Kite Pharma and gave the company a “buy” rating in a research note on Wednesday. Vetr lowered shares of Kite Pharma from a “buy” rating to a “hold” rating and set a $116.82 price target on the stock. in a research note on Monday, July 24th. Finally, Maxim Group lowered shares of Kite Pharma from a “buy” rating to a “hold” rating and set a $88.00 price target on the stock. in a research note on Thursday, July 13th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. Kite Pharma currently has an average rating of “Hold” and an average target price of $88.93.
Several institutional investors have recently made changes to their positions in KITE. Hussman Strategic Advisors Inc. acquired a new position in shares of Kite Pharma during the first quarter worth approximately $2,747,000. Great West Life Assurance Co. Can boosted its position in shares of Kite Pharma by 28.1% in the first quarter. Great West Life Assurance Co. Can now owns 5,013 shares of the biopharmaceutical company’s stock worth $392,000 after buying an additional 1,100 shares during the last quarter. Geneva Advisors LLC acquired a new position in shares of Kite Pharma during the first quarter worth approximately $1,347,000. Essex Investment Management Co. LLC boosted its position in shares of Kite Pharma by 8.0% in the first quarter. Essex Investment Management Co. LLC now owns 71,160 shares of the biopharmaceutical company’s stock valued at $5,585,000 after buying an additional 5,273 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its position in shares of Kite Pharma by 72.9% in the first quarter. Russell Investments Group Ltd. now owns 30,606 shares of the biopharmaceutical company’s stock valued at $2,403,000 after buying an additional 12,909 shares in the last quarter. 84.96% of the stock is currently owned by institutional investors and hedge funds.
Kite Pharma Company Profile
Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.
Receive News & Ratings for Kite Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.